Infarmed

Infarmed
Name	Autoridade Nacional do Medicamento e Produtos de Saúde
Formed	2001
Jurisdiction	Portugal
Headquarters	Lisbon
Chief1 position	President
Parent agency	Ministry of Health (Portugal)

Infarmed Infarmed is the national authority responsible for the regulation of medicinal products and medical devices in Portugal. It oversees marketing authorization, pharmacovigilance, market surveillance, and pricing within the Portuguese health regulatory framework. The agency interfaces with European and international bodies to align national practices with EU directives and World Health Organization standards.

History

The agency was established in the early 21st century amid reforms to align Portuguese pharmaceutical oversight with European Union directives, following precedents set by agencies such as the European Medicines Agency, Medicines and Healthcare products Regulatory Agency, and Agence nationale de sécurité du médicament et des produits de santé. Its creation paralleled modernization efforts in the Ministry of Health (Portugal), and coincided with regulatory developments after the Treaty of Lisbon and the expansion of the European Union pharmaceutical regulatory network. Over time the agency expanded competencies similar to counterparts in Spain, France, Germany, Italy, and United Kingdom. Notable milestones include adoption of pharmacovigilance systems influenced by the Council of the European Union legislation and participation in initiatives associated with the World Health Organization and the Organisation for Economic Co-operation and Development.

Responsibilities and Functions

The authority's remit covers evaluation and authorization of human and veterinary medicinal products, oversight of medical devices, control of clinical trial authorizations, and post-market surveillance. It implements pricing and reimbursement policies in coordination with the Ministry of Health (Portugal), interacts with payers such as the Serviço Nacional de Saúde and private insurers, and enforces compliance with directives from the European Commission and rulings of the Court of Justice of the European Union. The agency maintains pharmacovigilance databases that interoperate with systems from the European Medicines Agency, the World Health Organization, and national regulators including the Agência Nacional de Vigilância Sanitária and the Food and Drug Administration.

Organizational Structure

The institution is led by a president and supported by departments for medicinal products, medical devices, legal affairs, inspection, and international relations. Its governance model resembles structures used by the European Medicines Agency and the Health Products Regulatory Authority (Ireland), with advisory panels drawing expertise from universities such as the University of Lisbon, research institutes like the Instituto de Medicina Molecular, and hospital centers including Centro Hospitalar de Lisboa. Inspection units coordinate with customs authorities, law enforcement agencies including the Polícia Judiciária, and taxation bodies. Scientific committees comprise specialists from academic institutions, professional orders such as the Order of Pharmacists (Portugal), and representatives from industry associations like the Associação Nacional das Farmácias.

Regulation and Approval Processes

Marketing authorization procedures follow national pathways and participate in EU centralized, decentralized, and mutual recognition procedures administered via the European Medicines Agency. Clinical trial approvals align with the Clinical Trials Regulation and require dossier submissions comparable to standards set by the Food and Drug Administration and the European Commission. Pricing and reimbursement negotiations reference decisions by tribunals and frameworks influenced by the Court of Justice of the European Union and directives from the Council of the European Union. The authority applies guidelines from international standards bodies such as the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use and inspects compliance with good manufacturing practices established by the World Health Organization and the European Directorate for the Quality of Medicines & HealthCare.

Market Surveillance and Safety

The agency conducts market surveillance through inspections, adverse event reporting systems, and coordination with customs and police agencies to combat falsified medicines. It collaborates with the European Medicines Agency's networks, the Interpol Pharmaceutical Crime program, and the World Health Organization Global Surveillance and Monitoring System. Safety communications reach healthcare providers at institutions like Hospital de São José and community outlets such as the Associação Nacional das Farmácias, while recall actions follow procedures recognized by the European Commission and member state counterparts including agencies in Spain and France.

International Cooperation

The authority is active in European regulatory networks, contributing to committees within the European Medicines Agency, collaborating with the World Health Organization, and engaging bilateral ties with national agencies such as the Food and Drug Administration, the Medicines and Healthcare products Regulatory Agency, and the Agência Nacional de Vigilância Sanitária. It participates in multinational initiatives addressing antimicrobial resistance linked to the World Organisation for Animal Health and coordinates on cross-border public health responses with the European Centre for Disease Prevention and Control.

Criticisms and Controversies

The institution has faced scrutiny over timeliness of approvals, pricing decisions, and transparency in interactions with pharmaceutical companies and professional bodies like the Order of Pharmacists (Portugal), Associação Nacional das Farmácias, and multinational manufacturers. Debates have involved national policymakers in the Ministry of Health (Portugal), parliamentary committees of the Assembly of the Republic (Portugal), and watchdog organizations influenced by EU debates concerning regulatory independence, similar to controversies seen at the European Medicines Agency and the Food and Drug Administration. Concerns also arose during pharmacovigilance responses to high-profile safety issues tracked by the World Health Organization and media outlets in Portugal.

Category:Medical and health organisations based in Portugal